- Home
- JAGX
JAGX
Jaguar Health Inc.
as 12-18-2024 2:38pm EST
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 11.3M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 473.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.84 - $21.60 | Next Earning Date: | 11-13-2024 |
| Revenue: | $10,480,000 | Revenue Growth: | -2.25% |
| Revenue Growth (this year): | 32.33% | Revenue Growth (next year): | 43.63% |
Latest Jaguar Health Inc. News
JAGX Breaking Stock News: Dive into JAGX Ticker-Specific Updates for Smart Investing
ACCESSWIRE
a day ago
FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer for Treatment of Diarrhea in Cholera
CNW Group
2 days ago
FILAMENT HEALTH ANNOUNCES IMPORT OF COCA LEAF FROM PERU BY JOINT VENTURE MAGDALENA BIOSCIENCES
ACCESSWIRE
5 days ago
Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer
ACCESSWIRE
6 days ago
Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS)
ACCESSWIRE
9 days ago
Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS)
ACCESSWIRE
12 days ago
U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health’s Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins
ACCESSWIRE
13 days ago
Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine
GlobeNewswire
14 days ago
Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now
Compare JAGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JAGX Jaguar Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.